Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > Study compares 3 intrastromal injections for recalcitrant fungal keratitis
  • Cornea and External Disease

Study compares 3 intrastromal injections for recalcitrant fungal keratitis

Ophthalmology 360
Study compares 3 intrastromal injections for recalcitrant fungal keratitis

Intrastromal voriconazole (IS-VCZ), amphotericin B (IS-AMB) and natamycin (IS-NTM) are safe and effective as an adjunct to conventional therapy in patients with recalcitrant fungal keratitis, according to a study.

In this prospective randomized trial, 60 patients (60 eyes) with recalcitrant fungal keratitis who were not responding to topical natamycin (NTM) therapy for 2 weeks, were randomized to receive ISVCZ 50ug/0.1 mL (n = 20), ISAMB, 5ug/0.1 mL (n = 20), and ISNTM 10ug/0.1 mL (n = 20), in addition to continued topical NTM 5% every 4 hours until the ulcer healed.

Baseline parameters were similar in all groups. Compared to the ISVCZ group and the ISAMB group, mean duration of healing was significantly better in the ISNTM group.

In the ISVCZ and ISNTM groups, approximately 95% of patients healed successfully, whereas approximately 90% did in the ISAMB group. Deep vascularization was significantly greater in the ISAMB group compared to the other groups. Fewer repeat injections were needed in the ISNTM group compared to the other groups.

“The 3 intrastromal injections are comparable in efficacy and treating ophthalmologists can choose from any of these as an adjunct to conventional therapy for recalcitrant fungal keratitis,” the authors concluded.

Reference
Saluja G, Sharma N, Agarwal R, et al. Comparison of safety and efficacy of intrastromal injections of voriconazole, amphotericin B and natamycin in cases of recalcitrant fungal keratitis: A randomized controlled trial. Clin Ophthalmol. 2021;15:2437—2446.

Share

Related Content

  • Cornea and External Disease

Quiz: The impact of blepharitis and conjunctivitis on quality of life

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

  • Conference Roundup

Epioxa crosslinking system has positive outcomes at 30 months in patients with keratoconus

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon